Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
03/2005
03/16/2005CN1593459A Process for preparing arsenic magnetized nanometer glutin minipill
03/16/2005CN1593437A Adriacin or adriacin hydrochloride liposome injection and its preparing process
03/16/2005CN1593428A Dextran-aspirin combined medicine and its preparation method
03/16/2005CN1593425A Compound hyacinth bletilla minipill
03/16/2005CN1593424A Novel method for preparing anticancer photosensitizer of amphiphilic phthalocyanine and its application
03/16/2005CN1593417A Lipid emulsions of camptothecin derivative and its preparation
03/16/2005CN1593416A Method for preserving and preparing hydroxycamptothecine ring closure injection
03/16/2005CN1593403A Colon positioning and adhering preparation and its preparing process
03/16/2005CN1593402A Application of di-amino di-indoly cyclo-nonanoyl imide in the process for preparing anti-tumor medicine
03/16/2005CN1593400A Anticancer methylcantharidinimide tablet and its preparation method
03/16/2005CN1593390A Usage of honokiol in the preparing process of anti tumor angiopoiesis medicine
03/16/2005CN1193027C Substituted pyrroles
03/16/2005CN1193026C Z-pyrazoline-5-ones
03/16/2005CN1193025C Novel 1, 3-dihydro-2H-indol-2-one derivatives, their preparing method and pharmceutical composition containing the same
03/16/2005CN1193002C Compounds with particular structure and anticancer activity and its preparing process
03/16/2005CN1193000C Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharmaceutical and cometic compositions containing same
03/16/2005CN1192799C Adjuvant combination formulations
03/16/2005CN1192796C Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
03/16/2005CN1192778C Tumor cell growth inhibitor and its prepn process
03/16/2005CN1192774C Integerrimine liposome gel preparation and preparing method
03/16/2005CN1192772C Application of epigallic catechin 3-gallate in treating HPV infection
03/16/2005CN1192765C New and improved formulation for paclitaxel
03/15/2005US6867334 Treating mammalian leukemia; lung carcinoma; colon adenocarcinoma malignant melanoma; assaying the human cytochrome CYP3A4 metabolism of ecteinascidin 743
03/15/2005US6867299 Inosine monophosphate dehydrogenase (IMPDH); use as immunosuppressants, anticancer agents and antiviral agents
03/15/2005US6867231 Therapeutic systems
03/15/2005US6867227 Compounds that exhibit specific molecular recognition of mixed nucleic acid sequences and bind the DNA minor groove as a dimer
03/15/2005US6867219 Antitumor agents
03/15/2005US6867213 Vitronectin receptor inhibitors; bone diseases, osteoporosis; esterification of acid form with isopropanol
03/15/2005US6867211 Fused nitrogen biheterocyclic derivatives; immunomodulaters; inhibiting cytokine release
03/15/2005US6867208 Vitronectin receptor antagonists, their preparation and their use
03/15/2005US6867201 For therapy of abnormal cell growth, such as cancer, in mammals
03/15/2005US6867200 Anticancer agents; anticoagulants
03/15/2005US6867016 Reagents and methods useful for detecting diseases of the gastrointestinal tract
03/15/2005US6867007 Binary or polynary targeting and uses thereof
03/15/2005US6866857 Oxalipatinum preparation packaging
03/15/2005US6866851 GFRα1-RET specific agonists and methods therefor
03/15/2005CA2121678C Vitamin d amide derivatives
03/15/2005CA2054325C Antisense oligonucleotides for treatment of cancer
03/10/2005WO2005021776A2 METHODS OF USING MAMMALIAN RNase H AND COMPOSITIONS THEREOF
03/10/2005WO2005021739A1 ANTIBODY AGAINST Nox1 POLYPEPTIDE, METHOD OF DIAGNOSING CANCER WITH THE USE OF Nox1 GENE AND METHOD OF SCREENING CANCER GROWTH INHIBITOR
03/10/2005WO2005021595A1 Methods of antibody engineering using antibody display rules
03/10/2005WO2005021594A2 Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
03/10/2005WO2005021572A1 Ptp1b antisense compound
03/10/2005WO2005021555A1 Bicyclic piperazine compound and use thereof
03/10/2005WO2005021554A1 Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
03/10/2005WO2005021553A1 Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents
03/10/2005WO2005021552A1 Pyrimidothiophene compounds
03/10/2005WO2005021547A2 Heterocyclic cannabinoid cb2 receptor antagonists
03/10/2005WO2005021546A1 Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
03/10/2005WO2005021537A1 N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
03/10/2005WO2005021532A1 Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
03/10/2005WO2005021531A1 N-substituted benzimidazolyl c-kit inhibitors
03/10/2005WO2005021510A2 Benzimidazole c-2 heterocycles as kinase inhibitors
03/10/2005WO2005021046A1 Compositions and methods for delivery of biologically active agents
03/10/2005WO2005021029A2 Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris)
03/10/2005WO2005021013A1 β-HYDROXY SHORT TO MEDIUM CHAIN FATTY ACID POLYMER
03/10/2005WO2005021012A1 Drug carrier having gemcitabine enclosed therein
03/10/2005WO2005021003A2 Immunosuppressive effects of pteridine derivatives
03/10/2005WO2005020989A1 Cancer treatment with epothilones
03/10/2005WO2005020980A1 Acid containing oxaliplatin formulations
03/10/2005WO2005020913A2 Formulations, conjugates, and combinations of drugs for the treatment of neoplasms
03/10/2005WO2005020911A2 Benzo[1, 3]dioxole compounds, pharmaceutical compositions thereof, and processes of making and using the same
03/10/2005WO2005020901A2 Delivery of a therapeutic agent in a formulation for reduced toxicity
03/10/2005WO2005020900A2 Delivery of a therapeutic agent in a formulation for reduced toxicity
03/10/2005WO2005007192A3 Cytoprotection through the use of hif hydroxylase inhibitors
03/10/2005WO2005000355A8 Treatment of tumor by cotransferring chemotherapeutic agent with cytokine gene
03/10/2005WO2004108139A3 Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
03/10/2005WO2004096795A3 C-fms kinase inhibitors
03/10/2005WO2004089415A3 COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
03/10/2005WO2004087673B1 Migrastatin analogs and uses thereof
03/10/2005WO2004085654A3 Modulation of cell phenotype by inhibitory rna
03/10/2005WO2004081027A3 Neoplasm specific antibodies and uses thereof
03/10/2005WO2004048411A3 Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
03/10/2005WO2004041794A8 Antiinflammatory 3-arylthio-3-thiazolyl-alkylamines
03/10/2005WO2004012733A9 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
03/10/2005WO2004003166A3 Antibodies and uses thereof
03/10/2005WO2003104260A3 Pharmaceutical formulation
03/10/2005WO2003093409A3 Promoters exhibiting endothelial cell specificity and methods of using same
03/10/2005WO2003073062A3 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
03/10/2005WO2003010290A3 Novel class ii cytokine receptors and uses thereof
03/10/2005WO2001066772A9 Heparinase iii and uses thereof
03/10/2005US20050054851 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
03/10/2005US20050054835 Immunoglobulin fusion comprising gelonin and shiga-like toxin for use in treatment and prevention of graft vs host, autoimmue and cell proliferative disorders
03/10/2005US20050054820 Expression vector comprising nucleotide sequences coding calreticulin/heat shock protein fusion for use as tool in enhancement and induction of major histocompatibility complex immunological response; immunotherapy; tissue targeted therapy
03/10/2005US20050054717 Coumarin derivative
03/10/2005US20050054711 with a substituted benzene ring; agonists of the progesterone receptorinducing contraception treating progesterone-related carcinomas and adenocarcinomas
03/10/2005US20050054706 N-substituted pyrroles, pyrazoles, imidazoles, triazoles and tetrazoles used for treating and preventing cancer, inflammation, autoimmune diseases, respiratory system disorders, septic shock, pain, preterm labor, as dietetics and sexual disorders, and disorders associated with MAP kinases
03/10/2005US20050054675 Interferon $g(g) production promoter
03/10/2005US20050054674 Activator of peroxisome proliferator-activated receptor
03/10/2005US20050054672 Quinolinone derivatives
03/10/2005US20050054670 Angiogenesis inhibitors; anticancer agents; antiinflammatry agents
03/10/2005US20050054662 Quinazoline derivatives as antitumor agents
03/10/2005US20050054657 Induce immunology response; anticancer agents
03/10/2005US20050054655 Benzimidazole C-2 heterocycles as kinase inhibitors
03/10/2005US20050054653 Pteridine derivatives, method of producing them and their application
03/10/2005US20050054650 Suppression tumor growth
03/10/2005US20050054649 Probes for detecting the chaperone protein related to disease in biological samples; therapeutic treatment of cancer, autoimmune disease, inflammation, neurodegenerative disease, stroke, heart diseases
03/10/2005US20050054648 For therapy of cancer, including of breast neoplasma, endometrial cancer, colon cancer, and neck squamous cell carcinoma
03/10/2005US20050054638 Anticancer agents
03/10/2005US20050054637 Prophylaxis, therapy cardiovascular disorders
1 ... 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 ... 2211